|
1 |
Mon HC, Lee PC, Hung YP (洪逸平), Hung YW, Wu CJ, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. |
|
2 |
Huang BH, Li FY, Su SP, Chen CT, Chang KW, Yang MH (楊慕華), Chen MC, Chiang HK, Chan YH, Lee YJ. Integrating Ultrabright Polymer Dots and Stereo NIR-II Imager for Assessing Anti-Angiogenic Drugs in Oral Cancer Model. |
|
3 |
Ho WT, Chang JS, Lei CJ, Chen TC, Wang JK, Chang SW, Yang MH (楊慕華), Jou TS, Wang IJ. ROCK Inhibitor Enhances Resilience Against Metabolic Stress Through Increasing Bioenergetic Capacity in Corneal Endothelial Cells. |
|
4 |
Tang CY (唐振育), Lin YT, Yeh YC, Chung SY, Chang YC, Hung YP (洪逸平), Chen SC (陳三奇), Chen MH (陳明晃), Chiang NJ* (姜乃榕). The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer. |
|
5 |
Chung SY, Yeh YC, Huang CJ, Chiang NJ (姜乃榕), Hsu DS, Chan MH, Lu ML, Hsu TS, Hung YP (洪逸平), Yeh CN, Hsiao M, Chang YC, Wang YC, Chen MH* (陳明晃). Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma. |
|
6 |
Kao YC (高昀婕), Tsai YF, Shen SC, Dai MS, Chen FM, Liu LC, Chao TC (趙大中), Huang CC, Hou MF, Chen SC, Liu CY (劉俊宇), Tseng LM. Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer. |
|
7 |
Tseng YH, Tran TTM, Tsai Chang J, Huang YT, Nguyen AT, Chang IY, Chen YT, Hsieh HW, Juang YL, Chang PM (張牧新), Huang TY, Chang YC, Chen YM, Liu H, Huang CF. Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer. |
|
8 |
Lee CY, Yen HJ, Hou MH, Hung GY, Ho CY, Yu TY, Wu PK, Chen CM, Yen CC (顏厥全), Shiau CY, Chen PC, Wu HH, Wu CL, Chen WM. High dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma: A single institute experience in Taiwan. |
|
9 |
Peng HY, Chang CW, Wu PH, Li LJ, Lin YL, Hsiao M, Chang JY, Chang PM (張牧新), Lee HL, Chang WM. Oral Cancer-Derived miR-762 Suppresses T-Cell Infiltration and Activation by Horizontal Inhibition of CXCR3 Expression. Int J Mol Sci. 2025 Jan 26. (IF:4.9 / Ranking: BIOCHEMISTRY & MOLECULAR BIOLOGY 72/319; CHEMISTRY, MULTIDISCIPLINARY 70/329) |
|
10 |
Hung YP (洪逸平), Lee PC, Chang YH, Yang MH (楊慕華), Chiu CH, Chen MH (陳明晃), Lan KH, Lee IC, Hou MC, Chao Y (趙毅), Huang YH. Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non-Liver Malignancies in Hepatitis B Endemic Areas. |
|
11 |
Chen SC (陳三奇), Ho HL, Liu CA, Hung YP (洪逸平), Chiang NJ (姜乃榕), Chen MH (陳明晃), Chao Y (趙毅), Yang MH* (楊慕華). PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma. |
|
12 |
Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, Li D, Zhukova L, Zhu AX, Chen MH (陳明晃), Hack SP, Wu S, Liu B, Guan X, Lu S, Wang Y, El-Khoueiry AB. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. |
|
13 |
Tsai YF, Lai JI (賴峻毅), Liu CY (劉俊宇), Hsi CN, Hsu CY, Huang CC, Feng CJ, Lin YS, Chao TC (趙大中), Chiu JH, Tseng LM. Correlation Between PIK3R1 Expression and Cell Growth in Human Breast Cancer Cell Line BT-474 and Clinical Outcomes. |
|
14 |
Teng HW (鄧豪偉), Huang HY, Lin CC, Twu YC, Yang WH, Lin WC, Lan HY, Lin YY, Hwang WL. CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. |
|
15 |
Piercey O, Chantrill L, Hsu HC, Ma B, Price T, Tan IB, Teng HW (鄧豪偉), Tie J, Desai J. Expert consensus on the optimal management of BRAF^V600E-mutant metastatic colorectal cancer in the Asia-Pacific region. |
|
16 |
Hung YP (洪逸平), Huang YH. Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution-Authors' Reply. |
|
17 |
Huang CJ, Liu GT, Yeh YC, Chung SY, Chang YC, Chiang NJ (姜乃榕), Lu ML, Huang WN, Chen MH* (陳明晃), Wang YC. Construction of hot tumor classification models in gastrointestinal cancers. |
|
18 |
Ho IW (何奕緯), Tseng YR, Liu CY (劉俊宇), Tsai YF, Huang CC, Tseng LM, Chao TC (趙大中), Lai JI* (賴峻毅). Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer. |
|
19 |
Lin TI, Tseng YR, Dong MJ, Lin CY, Chung WT, Liu CY (劉俊宇), Tsai YF, Huang CC, Tseng LM, Chao TC (趙大中), Lai JI* (賴峻毅). HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer. |
|
20 |
Chen JS, Bai LY, Cheng HH, Chan SL, Zou JY, Shi X, Houchard A, Truong-Thanh XM, Chen MH* (陳明晃). Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan. |
|
21 |
Ho IW (何奕緯), Chiang NJ (姜乃榕), Lai JI (賴峻毅), Chang PM (張牧新), Chen SC (陳三奇), Hung YP (洪逸平), Chen MH* (陳明晃). Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma. |
|
22 |
Cheng WM, Li PC, Nguyen MT, Lin YT, Huang YT, Cheng TS, Nguyen TH, Tran TH, Huang TY, Hoang TH, Chen SY, Chu YC, Wu CW, Lee MF, Chiou YS, Liu HS, Hong YR, Chang PM (張牧新), Hu YF, Chang YC, Lai JM, Huang CF. Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions. |
|
23 |
Lai JI (賴峻毅), Jung KH, Shimizu C, Tiambeng ML, Tseng LM, Hsu DC, Ihm SY, Spiteri C, Tan EM, Qu S, Antill Y. Patients' and doctors' preferences in early-stage triple-negative breast cancer treatment in Asia-Pacific: a multi-territory discrete choice experiment using a cross-sectional survey. |
|
24 |
Chen TI, Chen MH (陳明晃), Yin SC, Lin CJ, Lam TK, Huang CW, Chen YT, Liu XR, Gao YZ, Hsu WL, Chen HY, Yeh TS, Koshiol J, Lee MH. Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study. |
|
25 |
Tsai YF, Hsu CY, Chiu YN, Huang CC, Chou SH, Lin YS, Chao TC (趙大中), Liu CY (劉俊宇), Chiu JH, Tseng LM. Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry. |
|
26 |
Peng HY, Huang YL, Wu PH, Li LJ, Peng BY, Wu CY, Lin YL, Hsiao M, Chang JY, Mu-Hsin Chang P(張牧新), Lee HL, Chang WM. The miR-876-5p/SOCS4/STAT3 pathway induced the expression of PD-L1 and suppressed antitumor immune responses. |
|
27 |
Lin YY, Lan HY, Teng HW (鄧豪偉), Wang YP, Lin WC, Hwang WL. Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1. |
|
28 |
Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Muñoz M, Lai JI (賴峻毅), Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. |
|
29 |
Tsai YC, Huang CJ, Chang JL, Chiang NJ (姜乃榕), Huang YS, Bandaru A, Hung SC, Shan YS, Lee GB. Application of CAPTURE Assay for Early Diagnosis and Prognosis in Bile and Blood of Cholangiocarcinoma. |
|
30 |
Yu HY, Lee CY, Hu YC, Lin LG, Chao Y (趙毅), Li CP. Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis. |
|
31 |
Yang WH, Huang BY, Rao HY, Ye P, Chen B, Wang HC, Chung CH, Wu HH, Yen HR, Wang SC, Cha JH, Yan X, Yang MH* (楊慕華), Hung MC. Ribonuclease 1 Induces T-Cell Dysfunction and Impairs CD8+ T-Cell Cytotoxicity to Benefit Tumor Growth through Hijacking STAT1. |
|
32 |
Chou MY, Yang MH* (楊慕華). Immunomodulation on tumor immune microenvironment in acquired targeted therapy resistance and implication for immunotherapy resistance. |
|
33 |
Wu MJ, Yang SM, Fang WK, Chen TJ, Wu CY, Hsu YJ, Shen CE, Cheng YC, Hsieh WC, Yuh CH, Yang MH (楊慕華), Kung HJ, Wang WC. KDM4C works in concert with GATA1 to regulate heme metabolism in head and neck squamous cell carcinoma. |
|
34 |
Lai KC(賴冠章), Hsu TL, Lin SY, Chiang NJ (姜乃榕), Chen MH (陳明晃), Chao Y (趙毅), Yang MH (楊慕華), Chen SC* (陳三奇). Real-world insights into cabozantinib efficacy in hepatocellular carcinoma: Real-world cabozantinib efficacy in HCC. |
|
35 |
Huang AY, Kuo YJ, Yang MH (楊慕華), Tai SK, Hang JF. Primary Laryngeal Squamous Cell Carcinoma with DEK::AFF2 Fusion: The First Case Report. |
|
36 |
Yen CC(顏厥全), Chen PC, Chen SC (陳三奇), Wu WC(吳紋綺), Yen CH, Lin YC, Wu PK, Chen CM, Wang JY, Chao TC (趙大中), Yang MH (楊慕華), Fletcher JA. Ferroptosis as a therapeutic vulnerability in MDM2 inhibition in dedifferentiated liposarcoma. |
|
37 |
Chiang NJ (姜乃榕), Lee JH, Chen MH (陳明晃), Chao Y(趙毅), Su WC, Bai LY, Wu SY, Hsu CH, Shan YS, Li CP, Chen SH, Chung WP, Hao WH, Chen LT, Lin CC. Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors. |
|
38 |
Lai JI (賴峻毅), Peng YC, Chang PM (張牧新), Chang YH, Chung HJ, Huang YH, Lin TP, Huang WJ, Wei TC, Huang TH, Yen CC* (顏厥全). Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma. |
|
39 |
Tseng YH, Tran TTM, Chang JT, Huang YT, Nguyen AT, Chang IY, Chen YT, Hsieh HW, Juang YL, Chang PM (張牧新), Huang TY, Chang YC, Chen YM, Liu H, Huang CF. Correction: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer. |
|
40 |
Vachhani P, Tan P, Watson AM, Wu SJ, Baker R, Cheung S, Lee SE, Chen CC (陳志丞), Chen TY, Hsiao HH, Lee JH, Masarova L, Tan SY, Baskar J, Charlton B, Findlay A, Hamprecht D, Jarolimek W, Leadbetter J, Miller J, Morgan K, Zahoor A, Hobbs G. A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis. |
|
41 |
Chao TC (趙大中), Gracia D, Ho CH, Chen HY, Huang CC, Tseng LM. Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy. |
|
42 |
Lai KC, Chen CW, Chang PM (張牧新), Liao YC, Wang CW, Hsieh CH, Huang TT. Correlation Analysis Between IFIT2 and HLA Class II in Oral Cancer. |
|
43 |
Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y (趙毅), Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. |
|
44 |
Ho YC, Chang MC, Lin WY (林妏霙), Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. |
|
45 |
Chiang NJ (姜乃榕), Bai LY, Ho IW (何奕緯), Hsu CH, Liang YH, Chiu CF, Lin CC, Chang KY, Chen SH, Tsai HJ, Lin YP, Chen LT, Lin CC. A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. |
|
46 |
Li H, Chiang CL, Kwak KJ, Lee HL, Wang X, Romano G, Saviana M, Toft R, Cheng TS, Chang Y, Hsiang BD, Liu GW, Mo X, Ma Y, Pan J, Rima XY, Kim TN, Reategui E, Shen CN, Chu YS, Croce C, Chang PM (張牧新), Yeh YC, Carbone DP, Huang CF, Chiang CL, Nana-Sinkam P, Lee LJ. Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer Diagnosis. |
|
47 |
Chiang HC, Yang CJ, Wang JY, Lin FC, Chiang NJ (姜乃榕), Chung TJ, Tseng YL, Sheu BS, Chang WL. Body Subcutaneous Fat Change Predicts Chemoradiotherapy Response and Prognosis of Esophageal Cancer Patients: A Cohort Study. |
|
48 |
Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators (鄧豪偉). Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. |
|
49 |
Mukherjee S, Patiyal S, Pal LR, Chang TG, Biswas S, Dhruba SR, Stemmer A, Singh A, Yousefi-Rad A, Chen TH, Wang B, Marino D, Shon W, Yuan Y, Faries M, Hamid O, Reckamp K, Waissengrin B, Ornelas B, Chu PY, Boudjadi S, Ley L, Akbulut D, Ahmar NE, Signoretti S, Braun DA, Joo H, Kim H, Osipov A, Figlin RA, Bar J, Barshack I, Day CP, Sargsyan K, Apolo AB, Aldape K, Yang MH (楊慕華), Atkins MB, Ronai ZA, Hoang DT, Ruppin E. Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology. |
|
50 |
Wu MS, Kao WY, Chiang MF, Chuang PH, Hsu SJ, Wang SY, Chang CW, Lin CC, Hung CH, Wu CH, Chen SC (陳三奇), Lee HL, Hwang JI, Liang PC, Lin SM, Wang CC. Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation. |
|
51 |
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators(楊慕華). INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. |
|
52 |
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators(陳明晃). Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. |
|
53 |
Chow YF, Chang PM* (張牧新). The new insights of surgery for locally advanced head and neck cancer. |
|
54 |
Lo KH, Huang KH, Fang WL, Lin SC, Hung YP(洪逸平), Chen MH (陳明晃), Wu CW, Kung CY. Characteristics and prognosis of skip lymph node metastasis in gastric cancer: a retrospective study. |
|
55 |
Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04(陳明晃). Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. |
|
56 |
Yoon SS, Chen CC(陳志丞), Lee SE, Chang H, Cheong JW, Hou HA, Lee WS, Lim SN, Moon JH, Ong KH, Dai Y, Liu C, Kawashima J, Goh YT. Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia. |
|
57 |
Wang SF, Chou CY, Chao YW, Chan TK, Yeh WY, Chiang CE, Chen CH, Lee HC, Tseng LM, Chang YL, Cheng HM, Liu CY* (劉俊宇). Impact of PIK3CA Mutations on the Clinical Benefits of CDK 4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: An Updated Pairwise and Network Meta-Analysis. |
|
58 |
Tang LQ, Liu SL, Yang MH (楊慕華), Wang HC, Zhou YJ, Yang KY, Li Q, Hui M, Chen XZ, Leu YS, Chen LT, Liu LT, Guo SS, Chen QY, Wang S, Zhu HQ, Shen HG, Wang Y, Guo Y, Mai HQ. GFH018 and toripalimab combination therapy for previously treated recurrent or metastatic nasopharyngeal carcinoma: Results from a phase 1b/2 study. |
|
59 |
Huang CC, Yeh YC, Cheng HF, Chen BF, Liu CY (劉俊宇), Tsai YF, Ho HL, Tseng LM. Comprehensive genomic profiling of Taiwanese triple-negative breast cancer with a large targeted sequencing panel. |
|
60 |
Too CW, Liang PC, Chotipanich C, Venkatanarashima N, Lo RH, Zhuang KD, Tan Z, Gogna A, Ng DC, Loke KS, Chao Y(趙毅), Worakitsitisatorn A, Boonsingma N, Lee RC. Real-world outcomes of selective internal radiation therapy with 90Y resin microspheres in HCC/mCRC: RESIN registry Asia. |
|
61 |
Chiang NJ (姜乃榕), Tang CY(唐振育), Bai LY, Chang PC, Chen WM, Kang ST, Chen SC (陳三奇), Chen MH* (陳明晃), Hsieh JC*. Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study. |
|
62 |
Huang WK, Tang YJ, Wu CE, Hou MM, Hsu HC, Su PJ, Chiang NJ (姜乃榕), Chen SC (陳三奇), Yeh CN, Chen JS, Chen MH (陳明晃), Hsieh CH, Chou WC. Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancer. |
|
63 |
Huang CC, Yeh YC, Tsai YF, Lin YS, Chao TC (趙大中), Liu CY (劉俊宇), Ho HL, Tseng LM. Comprehensive genomic profiling of Taiwanese triple-negative breast cancer samples with medium- and large-sized sequencing panels: A comparative study implicating treatment allocations. |
|
64 |
Lee IC, Wang HW, Teng W, Lin TJ, Chen CH, Lai HC, Lee TY, Chang CW, Hung CH, Dai CY, Hung YP (洪逸平), Shen YC, Su CW, Ho MC, Lee WC, Chau GY, Ting CT, Liang PC, Liu CA, Chang PY, Chen KY, Lin SM, Chen LT, Huang YH; TLCA Intermediate Stage HCC Working Group. Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular Carcinoma. |
|
65 |
Lin WY(林妏霙), Tsai CK, Yeh CM, Liu CJ. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. |
|
66 |
Tsai HJ, Chen MH (陳明晃), Wang HP, Hsiao CF, Chen YY, Chen JS, Yang MD, Tzen CY, Shan YS, Bai LY, Chan DC, Chu PY, Ho CL, Yang Y, Lin J, Lin HY, Chang CS, Wang CC, Hwang TL, Chen LT. Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study. |
|
67 |
Chen BF, Lai JI (賴峻毅), Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Chao TC (趙大中), Liu CY (劉俊宇), Tseng LM, Huang CC. Real-world evaluation of CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: Prognostic effect of proton pump inhibitor use. |
|
68 |
Lee JM, Tu CC, Fang CH, Lin SR, Wang SL, Lai WY, Tseng PW, Liao WE, Huang LY, Chao Y(趙毅), Chen MH* (陳明晃). Detecting HER2-positive circulating tumor cells in gastric cancer using a flow cytometry-based approach. |
|
69 |
Maruki Y, Yatabe Y, Mizoguchi C, de Almeida KY, Sookprasert A, Akewanlop C, Chen MH (陳明晃), Sirachainan E, Tu DV, Malik RA, Charoentum C, Hoo HFS, Yusak S, Liu TH, Ramachandran R, Sunpaweravong P, Voon PJ, Bakar NA, Mizusawa J, Okuma HS, Nakamura K, Morizane C, Okusaka T. FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan-Asian Study. |
|
70 |
Lin YJ, Ou DL, Su YY, Hsu CL, Hsiao CF, Ko BS, Chen SC (陳三奇), Wang HW, Wang JH, Wu YM, Jeng YM, Lee WC, Chou SC, Chen TW, Chiu CF, Lin JS, Hsieh CH, Lee CC, Shan YS, Cheng AL, Chen LT, Hsu C. Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration. |
|
71 |
Chiu W, Chen SC (陳三奇), Chao Y(趙毅), Lee JM. Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report. |
|
72 |
Lin HH, Chang CF, Lee TL, Hsu YB, Tai SK, Yang MH (楊慕華), Wang LW, Chu PY. Comparing the 7th and 8th Editions of AJCC Staging System for Hypopharyngeal Cancer Undergoing Surgery. |
|
73 |
Yang MH (楊慕華), Wu SY, Ho IW (何奕緯), Chiang NJ (姜乃榕), Hsaio CF, Lin CY, Lien MY, Chang PM (張牧新), Chen JH, Hsieh CY, Hong RL, Lee CT, Chen LT, Liu TW, Chiu CF, Bai LY. Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial. |
|
74 |
Huang YW, Kuo YJ, Chen MC, Rodrigues J, Lee TL, Chang CF, Hsu YB, Chu PY, Tai SK, Zhuo GY, Yang MH* (楊慕華). Deciphering the Worst Pattern of Invasion in Oral Cancer: Integrative Clinical, Pathological, and Multimodal Nonlinear Optical Imaging Insights. |
|
75 |
Lai IC, Kang YM, Wu YH, Hu YW, Huang PI, Lin YJ, Lee MJ, Shyr YM, Li CP, Wang SE, Chen MH (陳明晃), Chiang NJ (姜乃榕), Hung YP (洪逸平), Lin KH, Hsu SJ, Yu HY, Lin YF, Liu YM, Lan KL. Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience. |
|
76 |
Yang YF, He ZJ, Kuo HH, Lin YY, Kim CH, Cai HY, Chen CL, Hsiao M, Chen YC, Chang PM (張牧新), Chang YC. Targeting ESR1 restores SQSTM1-dependent autophagy and sensitizes ER-positive breast cancer to oxidative and radiation stress. |
|
77 |
Lin CC, Chang CY, Lin YZ, Cheng HH, Huang SC, Lin HH, Lan YT, Wang HS, Chang SC, Yang SH, Jiang JK, Chen WS, Teng HW (鄧豪偉), Yang YW. Early- vs. late-onset colon cancer: clinicopathological insights and survival outcomes in an East Asian cohort. |
|
78 |
Chen JL, Chu PY, Huang CT, Wang WL, Chang YY, Dai MS, Liu CY* (劉俊宇). Targeting SET to counteract Lyn activation demonstrates anti-cancer potential in diffuse large B-cell lymphoma. |
|
79 |
Huang KJ, Ho CT, Lee PC, Chen SC (陳三奇), Liu CA, Chou SC, Lee IC, Huang YH, Luo JC, Hou MC, Wu JC, Su CW. PIVKA-II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels. |
|
80 |
Lee PC, Li PY, Lee CY, Lin SR, Wu CJ, Hung YW, Chen YH, Chan JW, Mon HC, Lee CJ, Chi CT, Lee IC, Hou MC, Chao Y(趙毅), Huang YH, Lee JM. Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning. |
|
81 |
Chen TJ, Lo CJ, Wu MJ, Sit WY, Hsu HY, Huang YC, Lu CH, Chen YL, Fang WK, Yang SM, Chen PL, Haraguchi T, Hiraoka Y, Lin CY, Cheng ML, Yang MH (楊慕華), Kung HJ, Wang WC. GSH as an A-A Type Allosteric Activator of PKM2: Modulating Cancer Cell Homeostasis and Ferroptosis Susceptibility. |
|
82 |
Chiu PH, Lai KC, Wang HL, Chang YW, Wu WC(吳紋綺), Chen TH, Tsai YS, Song JH, Sun NY, Chau GY, Fang WL, Chen JP, Wang HM, Huang HC, Hsieh MC, Hua CH, Lien MY, Chang YF, Wang HC, Chien CY, Huang TL, Wang CC, Liu YC, Chen JP, Lu WC, Yiu CY, Lin CL, Lou PJ, Chu PY, Wang SC, Hung MC, Yang MH* (楊慕華). Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. |
|
83 |
Liu C, Chien LI, Hung YP (洪逸平), Lai TY, Huang CS, Hsu HS, Chen MH (陳明晃), Huang PI, Hsu PK. Surgical Resection after Chemoradiotherapy with a Higher Radiation Dose in Locally Advanced Esophageal Cancer: A Retrospective Study from Taiwan. |
|
84 |
Chen CH, Chen SC (陳三奇), Lee HJ. Factors associated with end-of-life quality in terminally ill cancer patients' last six months of life: a longitudinal study. |
|
85 |
Chen CT, Feng YH, Yen CJ, Chen SC (陳三奇), Hsu CH, Shao YY. Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma. |
|
86 |
u CH, Chang CW, Chen SC (陳三奇), Kao WY, Ting WY, Lu CH, Chuang KI, Ni CF, Hsieh YY, Wu MS, Su CW, Chang CC, Wu CH. Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma. |
|
87 |
Chen IS, Hsieh CC, Li CC, Wei YL, Cheng CC, Feng SW, Lee HL, Chiang NJ* (姜乃榕), Shen CH*, Hsu HP*. ACSL6 modulates docosahexaenoic acid-induced cytotoxicity to potentiate chemotherapy response in colorectal and breast cancer. |
|
88 |
Chen YC (陳奕潔), Lai JI (賴峻毅), Chang YH, Chung HJ, Lin TP, Huang YH, Wei TC, Chen MH (陳明晃), Yen CC (顏厥全), Chang PM* (張牧新). Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: A single-center real-world study. |
|
89 |
Harrington KJ, Rosenberg AJ, Yang MH (楊慕華), Geiger JL, Oliva M, Ahn MJ, Lim SM, Ince W, Bhatia A, Sheth S, Keam B, Metcalf R, Curtin JC, Toyoizumi K, Wade M, Yilmaz E, Kim P, Verheijen RB, Shah S, Baig M, Swiecicki PL. Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study. |
|
90 |
Wang CY, Lin CF, Yang HC, Liu CY (劉俊宇), Lai JI (賴峻毅), Wu HM, Chung WY, Shiau CY, Guo WY, Lee CC. Gamma knife radiosurgery for breast cancer brain metastasis: survival outcomes, prognotic factors, and the role of repeat treatment. |
|
91 |
Chen CH, Chen SC (陳三奇), Lee HJ. Changes in End-of-Life Quality in Patients With Terminal Cancer During Their Last 6 Months of Life: A Longitudinal Study. |
|
92 |
Lee KW, Bai LY, Jung M, Ying J, Im YH, Oh DY, Cho JY, Oh SC, Chao Y(趙毅), Kim JW, Chen Y, Li V, Chen S, Kang YK. Phase 1b/2 Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. |
最後更新：